Hallucinations, mainly of a visual nature, are considered in 25.5% of the patients (an isolated occurrence in 14.3%), formed visual hallucinations were present in 22.2% to affect about one-quarter of patients with Parkinson's disease. They are commonly viewed as a side-effect of (isolated in 9.3%) and auditory hallucinations were present in 9.7% (isolated in 2.3%). Patients with minor antiparkinsonian treatment, but other factors may be involved. The aim of this study was to determine the hallucinations had a higher depression score than nonhallucinators but did not differ in other respects. Logistic phenomenology, prevalence and risk factors of hallucinations in Parkinson's disease. Two-hundred and regression analysis identified three factors independently predictive of formed visual hallucinations: severe cognitive sixteen consecutive patients fulfilling clinical criteria for Parkinson's disease were studied. Demographic and disorders, daytime somnolence and a long duration of Parkinson's disease. These findings indicate that, when clinical variables were recorded, including motor and cognitive status, depressive symptoms and sleep-wake minor hallucinations are included, the total prevalence is much higher than previously reported. A simple sidedisturbances. Patients with and without hallucinations were compared using non-parametric tests, and logistic effect of dopaminergic treatment is not sufficient to explain the occurrence of all visual hallucinations. The regression was applied to significant data. Hallucinations had been present during the previous 3 months in 39.8% main risk factor in treated patients is cognitive impairment, although sleep-wake cycle disturbances, and of the patients, and fell into three categories: minor forms, consisting of a sensation of a presence (person), a sideways possibly other factors related to the duration of the disease, act as cofactors. passage (commonly of an animal) or illusions were present
Introduction
Although mental disturbances in the course of Parkinson's again attracted attention. First, several prospective studies showed that hallucinations, mainly visual, affected as many as disease, including delirium and hallucinations, were mentioned by early authors, they were thought to be rare and one-quarter of outpatients with Parkinson's disease (SanchezRamos et al., 1996; Graham et al., 1997; Inzelberg et al. , were considered by most clinicians to be either part of the ultimate progression of the disease or coincidental (Souques, 1998; Pappert et al., 1999) . Secondly, some investigators stated that hallucinations were a risk factor for permanent 1921). After an epidemic of lethargic encephalitis, the picture was blurred by the coexistence of Parkinson's disease and nursing home placement, with its associated high mortality rate Stebbins, 1993, 1995) . Thirdly, the postencephalitic cases, such as hallucinations and psychotic disorders, which were commonly observed in the course of management of hallucinations requiring antipsychotic treatment has been improved by the development of new postencephalitic syndromes (de Ajuriaguerra, 1971 ). In the years following the introduction of dopaminergic therapy, agents, such as clozapine, which may be used in Parkinson's disease patients with a low risk of aggravating motor confused states and hallucinations were reported as a sideeffect of levodopa and, later, of dopaminergic agonist therapy symptoms (Cummings, 1999) . Several questions regarding hallucinations in Parkinson's (Factor et al., 1995) .
Recently, the hallucinations of Parkinson's disease have disease remain controversial or unanswered. Minor forms of hallucination, such as the sensation of a presence, have been recall, calculation, crossed verbal fluency, set-shifting and similarities). The maximum total score is 32. According to reported but have not been studied systematically. The pathophysiology of the hallucinations is also poorly the validation studies, we classified cognitive status in three groups: normal (score between 32 and 29); moderately understood. Although hallucinations are commonly considered to be a side-effect of dopaminergic treatment, impaired (between 28 and 24); and severely impaired (below 24). Dementia was diagnosed by using the Diagnostic and various mechanisms have been implicated (Factor et al., 1995; Mendis et al., 1996; Manford and Andermann, 1998) Statistical Manual of Mental Disorders (DSM-IV) criteria A and B (American Psychiatric Association, 1994) . The use of and other factors may intervene. Previous clinical studies have shown that the presence of cognitive impairment is DSM criteria for the diagnosis of dementia in Parkinson's disease may raise some difficulties (see discussion in Mahieux associated with a higher risk of developing hallucinations (Meco et al., 1990; Sanchez-Ramos et al., 1996; Graham et al., 1998) , and in some cases the diagnosis of dementia may be questionable. For the purpose of statistical analysis, et al., 1997) . However, the role of other factors, such as motor status, sleep disorders and depression, is controversial.
we pooled the data for patients with certain dementia and suspected dementia. Mood was assessed using the French The aims of this study were to establish, in a large population of outpatients with Parkinson's disease, the prevalence and version of the Center for Epidemiologic Studies depression self-rating scale (CES-D) (Fuhrer and Rouillon, 1989) . characteristics of hallucinations, including minor forms, and to identify independent predictive factors for hallucinations Antiparkinsonian treatments were recorded, and the total daily dose of levodopa was calculated for each patient. In among a set of clinical variables by the use of multivariate analysis.
order to take into account the amount of all dopaminergic agents taken (i.e. levodopa and dopaminergic agonists), we calculated a levodopa-equivalent dose, using correspondences published previously or the available data comparing levo-
Methods
dopa and dopaminergic agonists (Vidailhet et al., 1990; Krack et al., 1998) , as follows: 10 mg bromocriptine ϭ 1 mg
Recorded data
Motor function was assessed using the Unified Parkinson's lisuride ϭ 4 mg ropinirole ϭ 100 mg levodopa (with a dopa-decarboxylase inhibitor). As no equivalency data were Disease Rating Scale (UPDRS) activities of daily living (UPDRS II) and motor (UPDRS III) subscales, and modified available for piribedil, a dopaminergic agonist available in France, we considered 100 mg piribedil equivalent to 100 mg Hoehn and Yahr staging (Fahn et al., 1987) . Because axial symptoms may depend on non-dopaminergic lesions and levodopa on the basis of primate studies (L. A. Smith, personal communication) and the clinical experience of have been found previously to correlate with cognitive impairment (Pillon et al., 1989) , we also calculated an 'axial French Parkinson's disease specialists. On the basis of previous studies and our own clinical score', defined as the sum of the following UPDRS III items: speech; rising from a chair; posture; postural stability; and experience, we routinely questioned the patients on the presence of three types of hallucinatory phenomena during gait (maximum score 20). In patients with fluctuating symptoms, the UPDRS II items were rated according to the the previous 3 months: minor hallucinations/illusions; visual hallucinations; and auditory hallucinations. Minor hallucinabest performance in the day, and the motor scores were determined while in the 'on' state. Patients were considered tions/illusions were defined as 'presence' hallucinations, 'passage' hallucinations and illusions (see description below). as fluctuating if they had akinetic fluctuations other than early-morning akinesia or corrected end-of-dose deterioration.
Earlier episodes of hallucinations were also recorded. The characteristics of the recent (ഛ3 months) hallucinations were They were considered as dyskinetic if they had dyskinesias scoring ജ2 on Obeso's scale (Langston et al., 1992) . recorded using a semistructured questionnaire. Patients were defined as having severe sleep disorders if they had two or more of the following: difficulty falling asleep; more than one awakening during sleep; early morning
Patients
The patients were recruited consecutively in two Parkinson's awakening; nocturnal agitation; and vivid dreams. Daytime somnolence (not including a short rest period after lunch) disease clinics located in Paris (Hôpital Tenon and Hôpital Léopold Bellan). The outpatients were included in the study was recorded according to statements of the patients and/or caregivers. The patients were asked if they had a known if they met the UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria for 'definite' Parkinson's disease ocular pathology (including cataracts, retinal disease and glaucoma).
( Hughes et al., 1992) , spoke fluent French and gave their informed consent. Two-hundred and sixteen patients were Global cognitive function was assessed using the MiniMental Parkinson (MMP), a recently developed and validated studied (141 from Tenon and 75 from Bellan). Their main characteristics are presented in Table 1 . Only seven patients bedside cognitive test that is adapted to Parkinson's disease cognitive disorders (Mahieux et al., 1995; Mahieux and received no antiparkinsonian treatment, and another five received selegiline and/or anticholinergics with no dopa Fénelon, 1998) . In brief, the MMP consists of seven subtests (orientation, visual memory registration, visual memory minergic treatment. One patient had received a unilateral in the study. The frequencies of the different forms of hallucinations are shown in Table 2 . In only two cases (2% of the patients with hallucinations) had the hallucinations intrastriatal graft of foetal mesencephalic cells and another occurred during the course of delirium (according to DSMpatient had received bilateral pallidal stimulation. None of the IV criteria), presumably related to antiparkinsonian treatment. patients had previously received a diagnosis of schizophrenia.
Remote transient episodes of hallucinations (occurring Ͼ3 One patient had a delusional disorder (persecutory type) months before inclusion), commonly during an acute psychknown before the onset of Parkinson's disease.
otic episode, had occurred in 35 patients (16.2%), 14 of Comparison of the patients recruited in the two centres whom had no hallucinations in the 3-month period preceding revealed few differences. Compared with the patients seen inclusion. Therefore, the total lifetime prevalence of halluat Bellan, those seen at Tenon Hospital had a lower UPDRS II cinations of all types was 46.3% (95% confidence interval ϭ score (mean 9.2 versus 13.4, P Ͼ 0.001), were less likely to 39.7-52.9). have akinetic fluctuations (31 versus 53%, P ϭ 0.002), received a lower daily dose of levodopa (mean 578 versus 759 mg, P ϭ 0.001) and were less likely to receive amantadine Phenomenology of the hallucinations (7.8 versus 18.7%) . All the other variables, as well as the
Minor hallucinations/illusions
prevalence of hallucinations, were not significantly different.
We grouped together in this category (n ϭ 55) three types of phenomena. The most frequent type was presence hallucinations (n ϭ 35, 64%). The patient had the vivid sensation of the presence of somebody either somewhere in the room
Data analysis
The statistical analysis was performed using non-parametric or, less often, behind him or her. In all cases, the presence was that of a person, and in one case it was also occasionally tests. The results are presented as mean Ϯ standard deviation in order to facilitate comprehension of the tables. We used the presence of an animal (a rat). In seven cases, the presence was that of a relative (deceased in three cases). In all the the Mann-Whitney two-tailed U-test for comparison of two subgroups of patients for continuous variables, the Kruskalother cases the presence was unidentified. The presence hallucinations were commonly as vivid as a hallucinated Wallis test for global comparison of three subgroups of patients for continuous variables, and the χ 2 test for categorscene and were described as a 'perception'. For instance, one patient said: 'the image is behind me', a second said: 'I ical variables. The multivariate analysis was performed using a stepwise logistic regression, submitting all covariates that see someone arriving; I turn back but nobody is there', a third said: 'I take a look; I don't see anything, but it is engraved showed statistical significance (P Ͻ 0.05). Continuous variables were dichotomized using the median as the cut-off in my mind', and another said: 'I have the impression that my mother is always there, that she is about to come into value. Cognitive disorders were classified into two subgroups according to the MMP score: severe (MMP Ͻ 24) and sight'. The passage hallucinations (n ϭ 18, 33%) consisted of brief visions of a person (six patients) or an animal (12 moderate or absent (MMP ജ 24). Statistical analyses were the evening, while clearing away the tables and chairs, he often had the brief sensation of a mouse passing on the right. patients) passing sideways. If an animal was seen, the species was almost invariably specified (commonly a cat or a dog), He turned his head to the right but could not see anything. and in two instances it was a dog previously owned by the patient. Illusions occurred in nine patients (16%). In five cases the illusion consisted of the transformation of an object
Formed visual hallucinations
Formed visual hallucinations occurred in 48 patients. They into an animal (e.g. a branch was seen as a cat for a few seconds).
had been present for a mean of 2.2 years (SD ϭ 1.8). Formed visual hallucinations consisted of persons, animals and, less Minor hallucinations/illusions occurred in patients on antiparkinsonian medication in all but one case. One de novo often, objects or other entities such as devils or 'Ninja turtles' ( Table 4 ). The hallucinated scenes were kinetic in 47% of patient, a 70-year-old man with no cognitive disorders, had the frequent sensation of an unidentified presence, which he cases. Visual hallucinations were more frequent in the evening and during the night in 46% of the patients and had no called his 'guardian angel'. Minor hallucinations were static in 53% of the patients. In 27% of the patients they occurred predominant schedule in 42%. They occurred daily in 29% of the patients, less than daily but at least once a week in predominantly in the evening or at night, and in 66% of the patients they had no specific schedule. In all cases but one, 39%, and more rarely in 18%. A single episode of visual hallucinations had occurred (in the 3 months preceding the sensation was very brief (Ͻ5 min, commonly a few seconds) and was rapidly dismissed by nearly all the patients. inclusion) in 14% of the patients. The duration of each hallucinatory episode was Ͻ5 min in 72% of cases. In When the minor hallucinations were isolated (i.e. without other forms of hallucinations, n ϭ 31), they had been present patients with diurnal akinetic fluctuations, there was no link between visual hallucinations and 'off' periods except in one for a mean duration of 0.9 years (SD ϭ 0.7), they were never mentioned spontaneously and they had few, if any, case. All the patients with visual hallucinations received dopaminergic treatment, but a modification of the treatment repercussions on the patients (Table 3) .
preceding the onset of visual hallucinations was recorded in only 19% of the patients. Visual hallucinations were associ-
Case 1 (presence hallucinations).
A 71-year-old woman had had tremor-predominant Parkinson's disease diagnosed ated with other types of hallucinations (minor or auditory) in 58% of the patients. Other characteristics of the visual 2 years previously, with no cognitive impairment (MMP score 31). She received levodopa, mianserin and lorazepam hallucinations and their consequences are summarized in Table 3 . Interestingly, insight into the hallucinatory nature of for an anxiety disorder. She had daily presence hallucinations for~6 months before inclusion. The patient lived on her own the phenomenon was maintained in all the patients without dementia and 64% of the patients with dementia (corrected and had a sister living somewhere else in Paris. During the night or when awakening in the morning, she had the vivid χ 2 ϭ 5.96, P Ͻ 0.02). Associated delusions were present in only 13% of the demented patients and in none of the nonsensation that her sister was lying beside her in the bed. She knew that this was not possible, but she used to lift the top demented patients (not significant). No cases of Capgras syndrome were recorded. sheet to check that her sister was not there. Later in the morning, when passing near her bed, she often again had the feeling that her sister was there and she checked again. Each
Case 3 (formed visual hallucinations).
A 71-yearold man had had Parkinson's disease for 8 years and was episode lasted only a few seconds. In only one instance, 2 months before inclusion, the patient had a brief, formed taking levodopa. His motor symptoms and signs were mild to moderate and he was independent in all daily activities. visual hallucination: she saw two persons in her bedroom, followed them to the living room and then realized they However, the patient had developed cognitive disorders about 4 years after the onset of motor symptoms. At the time of were unreal. inclusion in the study, the MMP score was 18 and the patient met DSM criteria for dementia. Hallucinations had started
Case 2 (passage hallucination).
A 59-year-old man, the owner of a café in Paris, received levodopa and bromocripduring a therapeutic trial of a dopaminergic agonist 4 years previously but had not subsided after the agonist was withtine for Parkinson's disease diagnosed 3 years previously. In drawn. They consisted of characters which commonly took three (14%) and consisted of various other noises (often the sound of steps) in 11 patients (48%). Deafness was present the form of small incorporeal devils with a blurred face and a changing size. They moved rapidly in 'a sort of haze'.
in two cases of musical hallucinations. During an episode of lumbar pain, the patient thought that these characters were armed with blades and were
Case 4 (auditory hallucination).
A 68-year-old-'butchering' his back. However, in most instances, the woman had received a diagnosis of Parkinson's disease 18 hallucinations of devils were not frightening and were well years previously. She was taking levodopa, bromotolerated. The patient said that he had become familiar with criptine, piribedil and amantadine. She had moderate cognitthem, that their lives were now intermingled with his own ive disorders (MMP score 25) and felt depressed. She had and that it was like 'living in a fantasy novel' or in a 'parallel experienced presence hallucinations (of an unindentified world'. The patient repeatedly stated that he was aware of person) for the last 6 months. In one instance she saw her the unreality of the visions, but admitted that he would deceased son with another person. Her son distinctly said to occasionally speak to them because they 'looked so real'.
her: 'take care of yourself'. Visual hallucinations occurred daily, predominantly at night, and the characters seemed to be 'scared' and 'scattered' by light, a noise or a sudden wave of the hand. The patient also
Comparison of hallucinators and nonexperienced presence hallucinations: 'it's a presence behind me; I try to catch it by turning round but I never see its face'.
hallucinators
The patients with isolated minor hallucinations (n ϭ 31) were compared with the patients with no hallucinations (n ϭ 130). The only significant difference was a higher CES-D
Auditory hallucinations
Auditory hallucinations occurred in 21 patients but were score (corresponding to more depressive symptoms) in the group with minor hallucinations (21.9 Ϯ 9.5 versus 17.5 Ϯ isolated (i.e. the hallucination consisted only of auditory phenomena) in only five cases (2.3% of the patients). In 9.2, P ϭ 0.02). When the presence of depression was determined using the cut-off values of the CES-D, depression most cases, auditory hallucinations were combined with visual hallucinations, either at different moments or simultanwas more frequent in the patients with minor hallucinations (50%) than in the patients without any hallucinations (34%), eously (in seven cases), like the sound-track of the scene (e.g. hallucinated persons were heard speaking). They could but this difference did not reach significance. The patients with formed visual hallucinations (n ϭ 48) also be combined with presence hallucinations. Auditory hallucinations were verbal in 13 cases (62%), musical in are compared with the non-hallucinators (n ϭ 130) in Table 5 . Patients with visual hallucinations differed in a number of respects: they were older, had a longer duration of disease, had a more severe motor state, had more depressive symptoms, and were more likely to have cognitive impairment, received a higher daily dose of levodopa, but the levodopaequivalent dose did not differ significantly between the two groups. Visual hallucinations were recorded in 70% of the patients with dementia (n ϭ 44) versus 10% of non-demented visual hallucinations were older and were more likely to be demented, according to DSM criteria, than non-hallucinators. patients (P Ͻ 0.001), and in 55% of the patients with severe cognitive disorders (MMP score Ͻ24, n ϭ 65) versus 8% of
The MMP score was lower in patients with visual hallucinations, although the difference reached significance only in the patients with absent or moderate cognitive impairment (P Ͻ 0.001).
patients with long-duration Parkinson's disease. Patients with visual hallucinations had a more severely affected motor The patients with hallucinations of any type (n ϭ 86) were compared with the patients with no hallucinations. The results state than non-hallucinators in the long-duration group only. were identical to those of the preceding analysis, except for the degrees of significance (data not shown).
A multivariate analysis was applied to the data on formed
Discussion
visual hallucinations. Three independent factors predictive Prevalence of visual hallucinations were identified: the presence of severe Only prospective studies should be taken into account when cognitive disorders, as defined by a MMP score Ͻ24; the discussing the prevalence of hallucinations during the course presence of daytime somnolence; and a disease duration of Parkinson's disease, because of the low frequency of selflonger than the median (8 years) (Table 6) .
reported hallucinations. This low frequency is explained by the ease with which a number of hallucinations are tolerated and by the fear of some patients of being considered insane.
Visual hallucinations according to the duration
In the only population-based study of psychotic symptoms in Parkinson's disease, the frequency of hallucinations and of Parkinson's disease
The prevalence of hallucinations of all types and of visual delusions during the week before evaluation was found to be 16% (Aarsland et al., 1999) . The results of recent hallucinations in the 3 months preceding inclusion in the study increased with the duration of Parkinson's disease prospective studies of hallucinations in outpatients with Parkinson's disease are summarized in Table 8 . The present (Fig. 1) . We compared the characteristics of the patients with and without hallucinations among those with a short history study and two other studies gave similar figures for the prevalence of visual hallucinations (22.2-25.7%) (Sanchezof Parkinson's disease (ഛ5 years, n ϭ 65) and those with a long history (Ͼ5 years, n ϭ 151). The results are shown in Ramos et al., 1996; Graham et al., 1997) . Similarly, Pappert and colleagues found that 26% of outpatients with Parkinson's Table 7 . Visual hallucinations had been present for a mean of 0.8 years (SD ϭ 0.3) in the patients with short-duration disease had hallucinations or illusions (Pappert et al., 1999) . The higher prevalence in one study (Inzelberg et al., 1998) Parkinson's disease and for 2.4 years (SD ϭ 1.8) in the patients with long-duration Parkinson's disease (P ϭ 0.03).
might be due to the older patient population involved. Interestingly, the rate of auditory hallucinations was similar However, eight patients with long-duration Parkinson's disease (n ϭ 42) and one patient with short-duration Parkinson's in three studies (~10%), while only one group recorded none. In the present study the total prevalence rate of hallucinations disease (n ϭ 6) could not remember the year of onset of visual hallucinations. In both groups, patients with formed in the 3 months before inclusion was nearly 40%. This high figure was obtained when minor forms of hallucinations were described by the patients in terms referring to imagery (e.g. 'the image is behind me'). Presence hallucinations taken into account.
have been described previously in other conditions, such as narcolepsy (Ribstein, 1976) and bereavement (Rees, 1971; Grimby, 1993) .
Phenomenology
To our knowledge, presence and passage hallucinations The formed visual hallucinations recorded in this study were similar to those described previously in patients with have not been studied systematically in Parkinson's disease until now, although presence hallucinations have been Parkinson's disease (Factor et al., 1995; Sanchez-Ramos et al., 1996; Graham et al., 1997) , consisting in most mentioned by other investigators (Sanchez-Ramos et al., 1996) . Presence hallucinations were the most common type cases of rather simple and non-threatening images of people or animals. Lack of insight and associated delusions in our series. Passage hallucinations and illusions are visual phenomena, but presence hallucinations cannot be related were present only in some patients with dementia. When auditory verbal hallucinations were present, they were to a specific sensory modality, although they were often always neutral and clearly different from the pejorative (Friedman, 1991; Factor et al., 1995) . This point of view is or threatening auditory hallucinations characteristic of supported by several arguments. First, 'psychotic' reactions schizophrenia.
were commonly recorded at the beginning of the levodopa era. Secondly, all the dopaminergic agents used in the treatment of Parkinson's disease may elicit adverse psychotic
Predictive factors and pathophysiology
reactions, there being a greater incidence with dopamine
Minor hallucinations/illusions
receptor agonists than with levodopa (Saint-Cyr et al., 1993) . Patients with isolated minor hallucinations/illusions differed Thirdly, in Parkinson's disease, 'psychotic' symptoms may from patients without hallucinations only by the presence of be reduced by a decrease in or cessation of dopaminergic more depressive symptoms on the CES-D rating scale, treatment (Friedman, 1991; Mendis et al., 1996) . In some suggesting that depressive symptoms are a facilitating factor.
cases, hallucinations disappeared after a 'drug holiday' and Indeed, depression may sometimes trigger or aggravate halluhad not recurred after 1 year (Koller et al., 1981) . cinations associated with deafness or ocular pathology However, other evidence indicates that hallucinations are (Fénelon et al., 1993) . However, when we analysed depression not a simple dopaminergic adverse event. First, in early according to CES-D cut-off scores, the difference between reports the frequency of acute psychic adverse reactions may the Parkinson's disease patients with minor hallucinations/ have been overestimated as larger doses of levodopa were illusions and those with no hallucinations was not significant.
used (Manford and Andermann, 1998) . Moreover, as stressed Interestingly, hallucinations involving the deceased spouse by Factor and colleagues, 'it is difficult to determine the (sense of a presence, and visual or auditory hallucinations) incidence with which these problems occurred because the have been reported in up to half of widowed persons, with early studies varied with regard to the inclusion criteria, a higher frequency in the elderly (Rees, 1971; Grimby, 1993) .
the dosages of levodopa employed, and the classification of In the present study, the 'presence' was that of a deceased the psychiatric effects reported ' (Factor et al., 1995) . In fact, relative in only three cases (8% of the presence hallucinahallucinations in the course of Parkinson's disease usually tions); bereavement cannot therefore explain the bulk of occur in a normal state of consciousness without delirium, the cases.
and have a chronic course (Goetz et al., 1998a, b ; Pappert Minor hallucinations may be a non-specific side-effect of et al., 1998). In our study, only two (2.3%) of the 86 patients antiparkinsonian drugs. However, one of the patients with a with recent hallucinations of any type fulfilled DSM-IV vivid presence hallucination was receiving no treatment. An criteria for delirium, and a recent change in antiparkinsonian alternative possibility is, therefore, that minor hallucinations/ drug dosage was found in only 19% of the patients with illusions are due to the disease itself, whatever its form and visual hallucinations. Secondly, hallucinations were recorded duration. Presence hallucinations might arise from a conflict before the use of levodopa (de Ajuriaguerra, 1971 ; Rondot between a preconscious visual perception (hallucinated) and et al., 1984) , but the data are difficult to interpret because most actual normal vision. Passage hallucinations are very brief studies were not prospective, patients with postencephalitic and are localized in the periphery of the visual field, and they are usually identified as a person or an animal of a syndromes were often included, and anticholinergic medicaparticular species. These characteristics suggest that passage tions were used widely. Thirdly, there is no simple dosehallucinations could arise from the misinterpretation of a effect relationship between dopaminergic treatment and the very flimsy perception due to disinhibition of an early part development of hallucinations. In the present study, the daily of the visual cognitive process, such as the perceptual dose of levodopa but not the daily levodopa-equivalent dose representation system. This system has been implicated by was significantly higher in patients with visual hallucinations. Tulving and Schacter in the priming effects on so-called However, this variable did not emerge as an independent data-driven implicit memory (Tulving and Schacter, 1990) .
predictive factor in the multivariate analysis. Moreover, in The system works at a presemantic level and accelerates the two prospective studies (Sanchez-Ramos et al., 1996 ; Graham recognition of previously encountered stimuli from very et al., 1997) and one retrospective study (Shergill et al. , slight cues. Patients with Parkinson's disease have been 1998), hallucinations were not associated with the dosage of reported to have an impairment in the process of ignoring dopaminergic medication (levodopa or dopaminergic agonirrelevant stimuli (Downes et al., 1989) . Thus, passage ists). Recently, Goetz and colleagues showed that there was hallucinations, and possibly other forms of minor hallucinanot a simple relationship between visual hallucinations and tions and illusions, could be rooted in false recognition high plasma levels of levodopa or sudden changes in plasma proposed by the perceptual representation system in response levels . This does not preclude a facilitating to very flimsy stimuli. A depressed mood could play a part or triggering action of dopaminergic treatment on hallucinaby decreasing attentional resources and the ability to inhibit tions, but eliminates a simple dose-related side-effect. irrelevant recognition.
Fourthly, non-dopaminergic pharmacological agents (mainly anticholinergics) may elicit hallucinations in Parkinson's disease patients (Saint-Cyr et al., 1993) . Fifthly, in a series
Dopaminergic agents and other treatments
of patients treated with dopamine agonists for pituitary The hallucinations of Parkinson's disease are commonly considered to be a side-effect of dopaminergic therapy tumours, hallucinations (mainly auditory) occurred in only 1% of cases (Turner et al., 1984) . Finally, hallucinations may pathological processes. On the one hand, impaired judgement, which is the hallmark of dementia, could lead to misinterpretaoccur spontaneously (i.e. in the absence of dopaminergic or other treatment), sometimes at presentation, in the course of tion of sensory stimuli. It could also be responsible for the lack of insight into the hallucinations and the presence of DLB (dementia with Lewy bodies) (Ala et al., 1997; Ballard et al., 1999) . As in Parkinson's disease, hallucinations in associated delusions, as in our study these features were present only in the patients with severe cognitive disorders. DLB are typically recurrent formed visual hallucinations (McKeith et al., 1996) . DLB may be clinically and pathologicOn the other hand, visual hallucinations could also be generated by an impairment in the processing of the visual ally difficult to distinguish from Parkinson's disease with dementia, and the boundaries between the two conditions are stimuli in the visual association cortices. Such a mechanism has been suggested to facilitate visual hallucinations in the blurred (McKeith et al., 1996) . It is therefore likely that the hallucinations of Parkinson's disease (more frequent when course of Alzheimer's disease (Holroyd and Sheldon-Keller, 1995) . Although the nature and pathophysiology of the dementia is present) and the hallucinations of DLB share mechanisms that are distinct from a side-effect of treatment.
changes are controversial, it is generally assumed that Parkinson's disease patients have deficits in visuospatial In the present study, non-hallucinators were more likely to be on anticholinergics or selegiline than patients with abilities, which progress as a function of advancing motor disease and the severity of dementia (Mohr et al., 1995) . Poor hallucinations. A similar paradoxical, negative association between anticholinergics and hallucinations was found by visuospatial performance also appears to be characteristic of DLB when patients with this disease are compared with Sanchez-Ramos and colleagues (Sanchez-Ramos et al., 1996) . This reflects the recommendation whereby the use of these Alzheimer's disease patients (Shimomura et al., 1998) . Interestingly, studies using PET have shown marked occipital drugs in patients with cognitive impairment is avoided because of the well-known risk of cognitive worsening hypometabolism in Parkinson's disease patients with dementia (Vander Borght et al., 1997) and in patients with DLB and/or hallucinations in this population.
( Albin et al., 1996) . Proposed mechanisms include diaschisis due to disruption of intracortical connections (Albin et al., 1996) and an occipital cholinergic deficit secondary to the
Cognitive impairment
We found that severe cognitive disorders were a major and degenerative processes in the basal nucleus of Meynert (Shimomura et al., 1998) . The more frequent involvement independent predictive factor for visual hallucinations. In other prospective studies, cognitive impairment was significof the visual cortex in Parkinson's disease dementia and DLB than in Alzheimer's disease could explain the higher antly more frequent in Parkinson's disease patients with visual hallucinations, whether cognition was studied using prevalence of visual hallucinations in the first two conditions. Another possibility is that the prevalence of hallucinations the Folstein Mini-Mental State Examination (Sanchez-Ramos et al., 1996; Aarsland et al., 1999) , the Blessed dementia is modified in different ways by pharmacological factors, i.e. it may be enhanced by dopaminergic agents in Parkinson's scale (Graham et al., 1997) or the 'short mental test ' (Inzelberg et al., 1998) . In a study of Parkinson's disease disease and reduced by neuroleptics in Alzheimer's disease. patients with dementia, 36% of the patients had hallucinations and/or delusions, and the Mini-Mental State Examination score was a significant predictor of these symptoms (Naimark
Sleep-wake disturbances
We found that day-time somnolence, but not severe sleep et al., 1996) . In the present study, 70% of the patients with dementia (according to DSM criteria) had visual hallucinadisorders, was an independent predictive factor for visual hallucinations. Moreover, we and others (Fernandez et al., tions. It is possible that the prevalence of hallucinations in demented Parkinson's disease patients is underestimated, as 1992; Sanchez-Ramos et al., 1996) have found that hallucinations in Parkinson's disease are more frequent in the evening visual hallucinations are rarely reported spontaneously and their presence is difficult to ascertain when the dementia and during the night, a feature shared by other forms of hallucinosis (e.g. peduncular hallucinosis and Charles Bonnet is severe.
Hallucinations, mostly visual, may occur in the course syndrome) and which is more likely to be due to alteration of arousal than to darkness (Manford and Andermann, 1998) . of degenerative dementias other than Parkinson's diseaseassociated dementia. We have already mentioned DLB, where
The association between hallucinations and sleep-wake disturbances in Parkinson's disease was first stressed by hallucinations are present in up to 70% of patients (Perry et al., 1995) . Visual hallucinations are also reported in up to Moskovitz and colleagues, who suggested that the symptoms progressed from vivid dreams to hallucinations, to delusions 25% of patients with Alzheimer's disease (Ballard et al., 1999) and in patients with frontotemporal dementia linked and finally to a confused state, this progression being due to a 'kindling' mechanism secondary to chronic dopatherapy to chromosome 17 (Foster et al., 1997) . In all these conditions, as emphasized in DLB, hallucinations may occur in the (Moskovitz et al., 1978) . Other investigators have also found a strong association between the psychiatric side-effects of absence of any pharmacological facilitating factor.
It is not clear whether cognitive changes and hallucinations levodopa and sleep disruption, and have suggested that sleep disruption is an early feature of 'levodopa psychosis' have a causative link or are independent consequences of the (Nausieda et al., 1982) . Recently, Pappert and colleagues history of depression more frequently (Sanchez-Ramos et al., 1996) or to have a higher score than non-hallucinators showed that 82% of Parkinson's disease patients with hallucinations had some form of sleep disorder (Pappert et al., on the Montgomery and Åsberg Depression Rating Scale (Aarsland et al., 1999) . In another study (Graham et al., 1999) . However, the authors found a close association between hallucinations and altered dream phenomena but not 1997), hallucinators with a disease duration Ͼ5 years had fewer depressive symptoms (as assessed by the Beck Depresssleep fragmentation. It should be emphasized that sleep disturbances are frequent in the course of Parkinson's disease, ive Inventory) than non-hallucinators. Conversely, a higher 'thought disorder' score (an item of the UPDRS which even in the absence of hallucinations, and data from clinical studies do not allow one to conclude that sleep disturbances includes hallucinations) was predictive of major depression in a study of risk factors for depression in Parkinson's as a whole and hallucinations are on a continuum and share a common pathophysiological mechanism. In this regard, disease (Tandberg et al., 1997) . The relationship between hallucinations and depression thus remains unclear. polysomnographic studies comparing Parkinson's disease patients with and without hallucinations could be valuable. We are aware of only one such study, which included five patients in each group (Comella et al., 1993) . Compared with
Ocular disorders
Visual hallucinations may occur in blind patients and in as non-hallucinators, patients with hallucinations had a lower sleep efficiency, a reduced total REM (rapid eye movement) many as 12% of cognitively normal people with poor visual acuity, a condition called the Charles Bonnet syndrome sleep time and a reduced REM percentage. These findings suggest a link between REM sleep abnormalities and the (Teunisse et al., 1996) . Moreover, it has been shown that decreased visual acuity is a risk factor for the presence of development of hallucinations during the course of Parkinson's disease. An association between a disturbance visual hallucinations in patients with Alzheimer's disease (Holroyd and Sheldon-Keller, 1995; McShane et al., 1995) . of the sleep-wake cycle and hallucinations occurs in other conditions, such as narcolepsy and peduncular hallucinosis.
Patients with Parkinson's disease may have a coincidental age-related ocular pathology responsible for visual deterioraLhermitte stressed similarities between dreams and peduncular hallucinosis and suggested that, in the latter condition, tion, facilitating the development of visual hallucinations. In the present study, patients with visual hallucinations were hallucinations might arise from a dysfunction of sleep-wake mechanisms secondary to the peduncular lesion (Lhermitte, more likely to have a known ocular disorder, but such disorders did not emerge as an independent predictive factor. 1922). Accordingly, lesions in Parkinson's disease might involve brainstem structures controlling sleep, especially This does not eliminate the possibility that ophthalmological abnormalities facilitate the development of visual hallucinathose generating REM sleep (Manford and Andermann, 1998) .
tions, at least in some patients with Parkinson's disease. Interestingly, visual hallucinations in the Charles Bonnet syndrome share some features with those occurring in the course of Parkinson's disease. They include a wide variety
Motor status
Previous studies showed that Parkinson's disease patients of images, all patients being aware of the unreal nature of the hallucinations and most not suffering as a result. Visual with hallucinations were more disabled than non-hallucinators (Sanchez-Ramos et al., 1996; Barclay et al., 1997; Graham hallucinations in Charles Bonnet syndrome are also more frequent in the evening or at night, suggesting that both et al., 1997). We also found that motor status was more severely affected in hallucinators than in non-hallucinators but sensory deprivation and a low level of arousal are facilitating factors (Teunisse et al., 1996 ; Manford and Andermann, did not emerge as a factor predictive of visual hallucinations in multivariate analysis. This could be due to the correlation of 1998). Specific, non-coincidental visual factors may also intervene motor impairment with the duration of the disease, the latter remaining a predictive factor in the multivariate analysis. In in the genesis of the hallucinations in Parkinson's disease. Patients with Parkinson's disease have subtle visual disturbpatients with fluctuating symptoms, we did not confirm the finding of Fernandez and colleagues that patients commonly ances related to the disease, including abnormalities in spatiotemporal contrast sensitivity and in colour discriminaexperience hallucinations only while in the 'off' state (Fernandez et al., 1992) .
tion. These changes have been ascribed to a retinal dopaminergic deficiency (Bodis-Wollner, 1990; Büttner et al., 1995) . The possible role of disease-related visual impairment in Parkinson's disease has been investigated by Diederich
Depression
We found that patients with formed visual hallucinations had and colleagues, who found that, in Parkinson's disease patients with normal acuity, those with visual hallucinations a higher CES-D score than patients without hallucinations, but this score was not a predictive factor in the multivariate had significantly worse performances in tests assessing colour vision and contrast discrimination (Diederich et al., 1998) . analysis. Recent prospective studies gave conflicting results about the link between hallucinations and depression in Another study has suggested an association between distorted chromatic contour perception and the presence of visual Parkinson's disease. Hallucinators were found to have a hallucinations in patients with Parkinson's disease (Büttner hallucinations/illusions, hallucinatory phenomena in Parkinson's disease are more frequent than has been described et al., 1996) . Therefore, coincidental ocular pathology or more subtle visual disturbances associated with Parkinson's previously: the total prevalence of hallucinatory phenomena in the 3 months preceding inclusion was nearly 40%, and disease may be facilitating factors for visual hallucinations.
the lifetime prevalence, which was possibly underestimated, was 46%. Although they were frequent, hallucinatory phenomena required a specific therapeutic change in only a
Hallucinations according to the duration of the minority of cases. This study dismisses a monofactorial view of the pathophysiology of hallucinations in Parkinson's disease
We found that the prevalence of hallucinations of all types disease, in which the hallucinations are a simple dose-related side-effect of dopaminergic treatment. Rather, pharmacoand of visual hallucinations in the 3 months preceding inclusion in the study increased with the duration of the logical agents, cognitive impairment, sleep-wake cycle disturbances, and possibly other factors related to the duration disease. Moreover, the duration of Parkinson's disease (and not the age at onset or at inclusion) was an independent of the disease, seem to act as cofactors in the genesis of hallucinations. Additional factors, such as depression and predictor of visual hallucinations in the multivariate analysis. Other studies gave conflicting results on the relationship visual disturbances, may contribute to the development (and/or influence the content) of the hallucinations, but their between hallucinations and disease duration. In a retrospective study of 100 patients, logistic regression analysis also showed potential role has to be investigated further. an association between 'psychosis' (mainly hallucinations) and an increased duration of the disease (Shergill et al., 1998) . An association between the duration of the disease
